Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
QXL-138AM by Nammi Therapeutics for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
QXL-138AM is under clinical development by Nammi Therapeutics and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According...
QXL-138AM by Nammi Therapeutics for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
QXL-138AM is under clinical development by Nammi Therapeutics and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to...
QXL-138AM by Nammi Therapeutics for Metastatic Pancreatic Cancer: Likelihood of Approval
QXL-138AM is under clinical development by Nammi Therapeutics and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData,...
QXL-138AM by Nammi Therapeutics for Metastatic Breast Cancer: Likelihood of Approval
QXL-138AM is under clinical development by Nammi Therapeutics and currently in Phase I for Metastatic Breast Cancer. According to GlobalData,...
QXL-138AM by Nammi Therapeutics for Multiple Myeloma (Kahler Disease): Likelihood of Approval
QXL-138AM is under clinical development by Nammi Therapeutics and currently in Phase I for Multiple Myeloma (Kahler Disease). According to...
QXL-138AM by Nammi Therapeutics for Metastatic Renal Cell Carcinoma: Likelihood of Approval
QXL-138AM is under clinical development by Nammi Therapeutics and currently in Phase I for Metastatic Renal Cell Carcinoma. According to...
QXL-138AM by Nammi Therapeutics for Metastatic Ovarian Cancer: Likelihood of Approval
QXL-138AM is under clinical development by Nammi Therapeutics and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData,...
QXL-138AM by Nammi Therapeutics for Gastrointestinal Tract Cancer: Likelihood of Approval
QXL-138AM is under clinical development by Nammi Therapeutics and currently in Phase I for Gastrointestinal Tract Cancer. According to GlobalData,...
QXL-138AM by Nammi Therapeutics for Metastatic Lung Cancer: Likelihood of Approval
QXL-138AM is under clinical development by Nammi Therapeutics and currently in Phase I for Metastatic Lung Cancer. According to GlobalData,...